This episode offers a detailed look into the FDA’s recent PCAC meeting and what the future of peptide compounding could lead to for pharmacy professionals.
News|Articles|September 15, 2003
New Product Newswire
New Product Newswire
Advertisement
Advertisement
Related to this article
Eli Lilly’s new indication helps improve medication delivery for adults with type 2 diabetes, reducing annual injections by over 300.
The update adds efficacy and safety data on adults newly diagnosed with pulmonary arterial hypertension.
The approval is the first new treatment advance in more than 30 years for chronic kidney disease for adults with type 1 diabetes.
Advertisement
Advertisement
Trending on Drug Topics
1
Muscle Preservation Is Key in GLP-1 Therapy for Postmenopausal Women
2
How the Main Street Pharmacy Access Act Advances Pharmacist Provider Status
3
Menopause Status, Symptoms Remain Inconsistently Documented
4
Pharmacy Law Lowdown: FDA’s Evaluation of Peptides
5